Wayne State University, USA.
Blood. 2013 Mar 14;121(11):1932-3. doi: 10.1182/blood-2013-01-480475.
In this issue of Blood, An et al(1) report that thrombotic disorders such as factor V Leiden are often treated with drugs like low molecular weight heparin (LMWH) to prevent placental failure and recurrent pregnancy loss. To date, the involvement of thrombotic mechanisms in this process is highly debated. An et al(1) have identified a new mechanism by which LMWH improves pregnancy outcome in a murine model of factor V Leiden that is unrelated to its anticoagulation capabilities.
在本期《Blood》中，An 等人(1)报告称，血栓性疾病（如因子 V Leiden）通常使用低分子肝素（LMWH）等药物进行治疗，以预防胎盘功能不全和复发性妊娠丢失。迄今为止，血栓形成机制在这一过程中的作用仍存在很大争议。An 等人(1)发现了一种新的机制，即 LMWH 通过该机制改善了因子 V Leiden 小鼠模型的妊娠结局，而与它的抗凝能力无关。
